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Abstract
Purpose
To study peripapillary choroidal thickness (PPCT) in healthy subjects using swept-source
optical coherence tomography (SS-OCT), and to evaluate PPCT differences between Par-
kinson´s disease (PD) patients, and age- and sex-matched healthy controls.
Design
Case-control study
Methods
80 healthy subjects and 40 PD patients were consecutively recruited in this single institution
study. The healthy subjects were divided into two populations: a teaching population (n = 40,
used to establish choroidal zones) and a validating population (n = 40, used to compare mea-
surements with PD patients). An optic disc 6.0×6.0 mm three-dimensional scan was obtained
using Deep Range Imaging (DRI) OCT Triton. A 26×26 cube-grid centered on the optic disc
was generated to automatically measure choroidal thickness. Five concentric choroidal
zones were established and used to compare PPCT between healthy and PD patients.
Results
PPCT was significantly thicker in PD patients compared with controls in all four concentric
zones evaluated (p0.0001). PPCT followed a similar pattern in controls and PD; it was
thicker in the temporosuperior region, followed by the superior, temporal, nasal, and inferior
regions.
Conclusion
PD patients presented with an increased PPCT in all zones surrounding the optic disc com-
pared with healthy subjects. The peripapillary choroidal tissue showed a concentric pattern,
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with the thickness increasing with increasing distance from the optic nerve. SS-OCT could
be useful for evaluating choroidal thinning in clinical practice.
Introduction
Parkinson’s disease (PD) is a neurodegenerative process that leads to the selective loss of dopa-
minergic neurons, mainly in the basal ganglia of the brain. Clinical manifestations include
movement alterations as well as non-motor symptoms, such as dementia, depression, and
autonomic dysfunction [1]. Neurons and neural circuits outside the basal ganglia can be
affected simultaneously or upstream of the substantia nigra [2].
Vision is one of the non-motor systems altered in PD, especially the visual field correspond-
ing to the fovea [3,4]. Recent studies demonstrated retinal thinning in different macular sec-
tors and retinal nerve fiber layers (RNFL) in PD patients compared with healthy subjects,
[5,6], and alterations in multifocal electroretinograms [7,8].
Several mechanisms have been proposed for the axonal loss in PD disease, leading to tissue
degeneration and ultrastructural changes of the retinal ganglion cells [9], but the changes of
the choroidal layer have not been thoroughly evaluated. Mechanobiologic response of tissues
[10] and cells [11] depends on the mode of deformation, and the magnitude and temporal pro-
file of the stimulus, as well as the type of tissue or cell and its biologic state. Understanding the
particular deformations observed in each tissue and ocular layer in patients with PD might
facilitate diagnosis and treatment.
Before the development of OCT, choroidal studies were limited to histopathologic analysis.
OCT is a useful tool for choroidal studies; nevertheless, the role of choroidal analysis for ocular
pathologies is not yet established. Spectral domain-optical coherence tomography (SD-OCT),
mostly with enhanced depth imaging (EDI), has been used to evaluate the macular and peripa-
pillary choroid (mainly in healthy eyes and glaucoma patients) [12,13], but the relation of
OCT measurements with changes in the peripapillary choroid remain unclear. Some studies
report a reduction in the mean or regional peripapillary choroidal thickness (PPCT) in pri-
mary open-angle glaucoma [14–16], but in these studies, choroidal thickness was measured
manually using SD-OCT at only a few points and beneath the circumpapillary ring, an area
typically used for RNFL evaluation. The automated segmental measurement software used in
the present study, however, is better suited for a broader and more objective evaluation of cho-
roidal thickness. Swept-source (SS) OCT, as compared with SD-OCT with EDI, provides bet-
ter visualization of the choroid [17], more accurately measures the deep tissues, detects the
posterior limit of the sclera, [18], and is applicable for evaluating a broader area of the posterior
segment.
Based on the improved ability of this new SS-OCT technology to reveal and automatically
measure a wide area of the peripapillary choroid, our first objective was to measure the PPCT
in a 26×26 cube-grid centered on the optic disc, which is automatically performed by the Deep
Range Imaging (DRI)-OCT Triton (Topcon Corporation, Tokyo, Japan), in a sample of
healthy subjects to determine the pattern or distribution of PPCT and to establish objective
zones with similar choroidal thicknesses. Our second objective was to study the PPCT differ-
ences within these zones in a sample of PD patients compared with age- and sex-matched
healthy controls. The third objective was to evaluate the relationship between PPCT alterations
and PD severity. The main advantage of the present study is that PPCT was evaluated in a
wide area of the peripapillary choroid using an automatic and accurate new method.
Choroidal thickness in Parkinson’s
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Material and methods
Study population and design
This was a prospective, observational, cross-sectional case-control study. The study included
patients with definite PD, and age- and sex-matched healthy controls. Based on our prelimi-
nary studies, we calculated the necessary sample size to detect differences in choroidal thick-
ness of at least 20 μm as measured by OCT, applying a two-tailed test with an alpha of 5% and
a beta of 10%, and a risk ratio of 0.5. Based on this calculation, at least 70 eyes were needed (35
from PD patients and 35 from healthy controls). A total of 40 eyes of 40 PD patients and 80
eyes of 80 healthy controls were evaluated. PD diagnosis was based on the UK Brain Bank Cri-
teria, which included, in the first stage, bradykinesia and one additional symptom, i.e., rigidity,
4–6 Hz resting tremor, or postural instability [19,20].
Patients with a visual acuity less than 0.1 (Snellen scale), intraocular pressure (IOP) >20
mmHg, optic neuritis antecedent, no transparent ocular media (nuclear color/opalescence,
cortical or posterior subcapsular lens opacity1 according to the Lens Opacities Classification
System III system) [21] and systemic disease that could affect the eye (e.g., diabetes, neurologic
pathologies, hypertension, and endocrine disorders) were excluded from the study. Subjects
with refractive errors greater than 5 diopters (D) of spherical equivalent refraction or 3 D of
astigmatism were also excluded from the study.
Standard protocol approvals, registrations, and patient consent
The study procedures were performed in accordance with the tenets of the Declaration of Hel-
sinki, and the study protocol was reviewed and approved by the Aragon Ethics Committee For
Clinical Research before the study began. Written informed consent to participate in the study
was obtained from all subjects.
Main outcome measures
All subjects underwent a complete neuro-ophthalmic examination, including assessment of
best-corrected visual acuity using the Snellen chart, pupillary reflexes, and ocular motility;
examination of the anterior segment, IOP with the Goldmann applanation tonometer, and
papillary morphology by funduscopic exam; as well as OCT.
In the PD group, disease severity was assessed using the Unified Parkinson Disease Rating
(UPDRS) and the Hoehn and Yahr scales, and disease duration since the PD diagnosis was
recorded. The Hoehn and Yahr scale is a commonly used diagnostic tool for quantifying the
progression of PD symptoms [22]. Stages range from 0 (no signs of disease) to 5 (requiring a
wheelchair, or bedridden unless assisted). Clinicians and researchers most commonly use the
UPDRS, and the motor section in particular, to follow the longitudinal course of PD in clinical
studies [23]. The scale includes three sections that evaluate the key areas of disability, and a
fourth section that evaluates treatment complications. Treatment for PD was registered using
three different categories for clearer classification: “drugs that enhance dopamine levels” (car-
bidopa, levodopa, and rasagiline), “dopaminergic drugs” (pramipexole, ropirinole, rotigotine),
and “other” (amitriptyline, propranolol, clonazepam).
OCT
An optic disc 6.0×6.0 mm three-dimensional scan was obtained using the DRI OCT Triton
(Topcon Corporation). This scan combines morphometric optic disc parameters and various
peripapillary parameters, including RNFL and choroidal thickness. The subjects were seated
and properly positioned. All DRI-OCT images were obtained by a single well-trained
Choroidal thickness in Parkinson’s
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technician blinded to the presence or absence of PD. The DRI-OCT Triton includes the new
SMARTTrack tool that enhances tracking, corrects for motion, and guides the operator to re-
duce potential errors while acquiring images. Only eyes with good quality scans were included
in the analysis. Good-quality SS-OCT images were defined as those with a signal strength40
(maximum = 100), and without motion artifact, involuntary saccade, or overt misalignment of
decentration. A total of three eyes (two in the PD group and one in the control group) were
excluded due to poor DRI-OCT image quality. These eyes were substituted with two new pa-
tients in the PD group and one new healthy subject in the control group. The same investigator
performed all of the OCT scans and checked the accuracy of segmentation in each scan and
the lack of artifacts. A total of 15 scans in the PD group and 10 in the control group were
excluded and repeated.
A 26×26 cube-grid centered on the optic disc was generated to automatically measure cho-
roidal thickness. This grid comprised 676 cubes (200 μm x 200 μm) around the optic nerve
head with the 88 central cubes corresponding to the optic nerve head area not analyzed; there-
fore the DRI-OCT Triton displays choroidal thickness for a total of 588 peripapillary cubes
(Fig 1). The Bruch membrane and choroidal-scleral interface were delineated with the segmen-
tation algorithm implemented by Topcon (Fig 1).
A total of 120 eyes were analyzed
80 healthy controls and 40 PD patients. The healthy control group was randomly divided in
two populations: the teaching population (n = 40 controls, used to establish choroidal zones)
and the validating population (n = 40 controls, used to compare measurements with PD
patients). Sex and age were not significantly different between the control groups or between
each of the control groups and the PD group. Only right eyes were selected for the statistical
analysis, because choroidal thickness is reported to differ between right and left eyes [23,24].
Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS
20.0, SPSS Inc., Chicago, IL). The Kolmogorov-Smirnov test was used to assess the sample
Fig 1. Left: Image of 26×26 cube-grid centered on the optic disc generated to automatically measure choroidal thickness with Deep Range Imaging (DRI)
optical coherence tomography (OCT) Triton (Topcon Corporation, Tokyo, Japan). This grid includes 676 cubes (200 μm x 200 μm) around the optic nerve
head, but the 88 central cubes corresponding to the optic nerve head area were not analyzed; therefore the DRI-OCT Triton displayed a choroidal thickness
for a total of 588 peripapillary cubes. The selected cube marked in the example of Fig 1B corresponds with row number 9 and file number 9. Right: The
Bruch membrane and choroidal-scleral interface were delineated with the segmentation algorithm implemented by Topcon.
https://doi.org/10.1371/journal.pone.0177163.g001
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distribution of the variables. For quantitative data following a parametric distribution, differ-
ences between evaluation groups were compared using the Student´s t-test. For qualitative
data, a chi square test was used for comparison. We delimited four areas based on the range of
choroidal thicknesses and compared the average of these areas between the PD and control
groups. We also compared choroidal thicknesses and volume in the four quadrants and six sec-
tors provided by Triton OCT between PD patients and healthy controls. To calculate volume,
we computed the thickness of the four quadrants and the six sectors, and total thickness rela-
tive to the effective imaging area; i.e., the total imaging area (peripapillary constant area, 27.04
mm2) minus the optic nerve head area (variable area, 3.52 mm2). We evaluated the linear
agreement between PPCT and the two neurologic scales of PD severity (the UPDRS and the
Hoehn and Yahr scales) using the Pearson correlation coefficient. A p value of less than 0.05
was considered statistically significant.
Results
Teaching population evaluation to establish peripapillary choroidal zones
The teaching population comprised 40 right eyes from healthy subjects and was used to iden-
tify 5 choroidal zones. The mean age of this population was 69.0 ± 7.9 years (range, 62–84
years). Of the 51 subjects, 14 (35%) were women. Mean spherical equivalent was 1.10 ± 1.35 D.
Study zones were previously set regarding the thickness of the cubes for each acquisition
point. Zone 1 corresponded to the optic nerve head area, and thus was not measured by the
OCT and not incorporated into the study. Zone 2 included the cubes with a choroidal thick-
ness of less than 105 μm, zone 3 included cubes with a thickness of 105 to 139 μm, zone 4
included cubes with a thickness of 140 to 174 μm, and zone 5 included cubes with a thickness
of 175 μm or greater (Fig 1).
The mean choroidal thickness in zone 2 was 95.00 ± 8.20 μm and included 120 cubes of the
choroidal grid; in zone 3 the mean thickness was 121.84 ± 9.56 μm and included 248 cubes; in
zone 4 the mean thickness was 156.58 ± 9.07 μm and included 181 cubes; and in zone 5 the
mean thickness was 186.90 ± 8.82 μm and included 31 cubes (Fig 2).
Figs 3 and 4 show the five zones in the teaching population of healthy controls, that are
roughly concentric to the optic nerve head, zone 2 mainly (the thinnest of the study zones with
a minimum mean PPCT of 78 μm) located nearest the optic nerve head and inferior peripapil-
lary choroid, zone 3 was mainly located in the inferior and nasal peripapillary choroid, zone 4
(around zone 3, especially in the temporal and superonasal areas), and zone 5 (the zone with
the maximum mean PPCT of 205 μm, corresponding to the farthest cubes, mainly located in
the superior and temporal peripapillary choroid).
Validating population and statistical comparison between healthy and
PD eyes
Once the study zones were established, a statistical comparison between control and PD eyes was
performed on a different population of control eyes. A total of 40 right eyes from healthy subjects
(independent from those subjects used in the teaching population) and 40 right eyes from PD
patients were included in the study. The mean age of the healthy control group was 68.58 ± 7.17
years (range: 61 to 85 years) and the mean age of the PD group was 69.76 ± 6.45 years (range: 62
to 85 years). Of the 40 subjects in each group, 14 (35%) were women. Mean spherical equivalent
was 0.13 ± 1.88 D in the control group (range, -2.50 to 2.50) and 0.14 ± 1.76 D in the PD group
(range, -2.75 to 2.50). Age, sex, and spherical equivalent did not differ significantly between
groups (p<0.05). The study population characteristics are summarized in Table 1.
Choroidal thickness in Parkinson’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0177163 May 16, 2017 5 / 13
“Drugs that enhance dopamine levels” was the most prescribed category (87% of patients)
and combination therapy with levodopa and carbidopa was the most frequent treatment
(46%). Sixty-five percent of treatments were categorized as “dopaminergic”, most of which
were used in combination with the drugs included in the “Drugs that enhance dopamine lev-
els” category. A small percentage of patients (8%) were prescribed drugs with no dopaminergic
effects.
Comparison of the PPCT between the healthy controls and the PD eyes in the five zones de-
scribed revealed a statistically thicker choroidal layer in all zones in the PD group (p<0.0001;
Fig 2. Schematic representation of the 5 zones defined in the 26×26 cube-grid using the peripapillary
choroidal thickness measurements in the teaching control population: Zone 1, corresponding with
optic nerve head in grey; zone 2 corresponds with mean peripapillary choroidal thickness (PPCT)
<105 μm and is represented in yellow; zone 3 corresponds with mean PPCT ranging from 105 to
139 μm, and is represented in green; zone 4 corresponds with mean PPCT ranging from 140 to 174 μm,
and is represented in blue; and zone 5 corresponds with mean PPCT175 μm and is represented in
orange. Bottom table: Mean PPCT ± standard deviation of each zone for the three groups evaluated (teaching
control group, validating control group, and Parkinson´s disease group).
https://doi.org/10.1371/journal.pone.0177163.g002
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Table 1 and Fig 2). The choroid followed a similar pattern in controls and PD; it was thicker in
the superotemporal region, followed by the temporal, nasal, and inferior regions, as shown
Figs 3 and 4. PPCT was higher in PD patients. The choroidal thicknesses did not correlate with
disease severity.
Evaluation of choroidal thicknesses in classic tomographic areas
The parapapillary choroidal thicknesses of the quadrants and sectors provided by the OCT
analysis were also compared between PD patients and healthy controls, and revealed a signifi-
cant increase in patients (Table 2).
Discussion
The involvement of the choroid in PD is unknown. To our knowledge, Eraslan et al.[25] pub-
lished the only study that discusses the choroid in relation to PD and suggested that choroidal
thickness is significantly diminished in PD patients [25]. In that study, a smaller sample size
was evaluated and the measurements of the choroidal plexus were obtained using SD-OCT
EDI. In SD-OCT EDI, the inner and outer borders of the choroid are determined manually by
the observer [23], and the error in the thickness measurements must be estimated from the
obtained images. In the present study, we used SS-OCT, in which the tunable laser source has
a lower signal decay versus depth than previous SD-OCT devices. Thus, the chorioscleral bor-
der is more clearly delineated due to the reduction in speckle noise, providing more accurate
manual and automated three-dimensional images of the retina and choroid [26]. In addition,
Fig 3. Three-dimensional graphical representation of the peripapillary choroidal thickness (PPCT) measurements in controls eyes (teaching population in
left fig, validating population in middle fig) and Parkinson´s disease (PD) eyes in right fig. Grey, cubes corresponding with the optic nerve head; yellow,
PPCT <105 μm; green, mean PPCT ranging from 105 to 139 μm; blue, mean PPCT ranging from 140 to 174 μm; and orange, mean PPCT175 μm.
https://doi.org/10.1371/journal.pone.0177163.g003
Fig 4. Representation of the mean peripapillary choroidal thickness (PPCT) for the 26×26 cube-grid centered on the optic disc for the three groups: the 40
right healthy eyes of the teaching population (left fig), the 40 right eyes of the healthy validating population (middle fig), and the 40 right eyes of the Parkinson
´s disease (PD) patient group (right fig). Grey, cubes corresponding with the optic nerve head; yellow, mean PPCT <105 μm; green, mean PPCT ranging from
105 to 139 μm; blue, mean PPCT ranging from 140 to 174 μm; and orange, mean PPCT175 μm. The temporosuperior choroid is the thickest, followed by
superior, temporal, nasal, and inferior choroid.
https://doi.org/10.1371/journal.pone.0177163.g004
Choroidal thickness in Parkinson’s
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with the SS-OCT device, observers only analyze a circle scan (SS-OCT only evaluates 12 cen-
tral degrees around the optic nerve and reports manual measurements of the choroidal thick-
ness for various points within this small area) [12], while the DRI-OCT used in our study
provides a total of 588 automatic measurements of the choroidal thickness, with each measure-
ment covering a broader area around the optic nerve (5.2x5.2 mm, corresponding to approxi-
mately 20 central degrees). Our present results revealed a significantly thickened choroid in
the peripapillary area, which is opposite to the findings for the retina in PD and to the Eraslan
et al. results [25].
RNFL thickness measurements by OCT are considered a useful indirect marker of the pro-
gression of brain atrophy in patients with PD [6,27]. Previous studies demonstrated macular
thinning of all areas in PD patients compared with controls, [5,6], an inverse correlation with
Hoehn and Yahr and UPDRS severity, and a positive correlation with the Schwab-England
Activities of Daily Living scale [27]. Therefore, increased neurologic effects and severity of PD
progression are linked to thinning of macular tissue [27]. Typical ophthalmic findings in PD
Table 1. Descriptive, clinical data, choroidal thicknesses and volume for eyes of patients with Parkinson’s disease and from healthy controls (vali-
dating population).
PD PATIENTS CONTROLS P*
Number of eyes 40 40 -
Age (years) 69.8 ± 6.5 68.6 ± 7.2 0.137
Sex (men/women) 26/14 26/14 0.901
Spherical Equivalent (D) 0.14 ± 1.76 0.13 ± 1.88 0.388
Number of myopic subjects (%) ** 18 (45%) 17 4(42.5%) 0.404
Number of hyperopic subjects (%)** 6 (15%) 6 (15%) 0.945
BCVA (LogMAR) 0.11 ± 0.17 0.03 ± 0.16 0.005
IOP (mm Hg) 16.5 ± 2.0 16.2 ± 2.8 0.439
Disc area (mm2) 1.92 ± 0.37 1.89 ± 0.37 0.309
Unified Parkinson Disease Rating Scale 25.1 ± 5.4 - -
Hoehn and Yahr Scale 2.7 ± 0.8 -
Disease duration (years) 6.7 ± 2.3 - -
Choroidal thickness (μm)
Zone 2 126.89 ± 11.23 96.53 ± 9.55 <0.0001
Zone 3 152.75 ± 16.00 121.39 ± 12.10 <0.0001
Zone 4 190.21 ± 12.16 156.69 ± 12.44 <0.0001
Zone 5 213.21 ± 11.83 186.64 ± 9.47 <0.0001
Total 163.01 ± 29.90 131.51 ± 30.22 <0.0001
Number of peripapillary cubes
70–104 μm thick 0 116 <0.0001
105–139 μm thick 165 258 <0.0001
140–174 μm thick 202 175 <0.0010
175 μm thick 221 39 <0.0001
Comparison of the choroidal thicknesses in the four established zones in the control group and Parkinson’s disease patients, and comparison between
groups. Comparison of the number of peripapillary cubes with a thickness from 70 to 104 μm (zone 2), from 105 to 139 μm (zone 3); from 140 to 174 μm
(zone 4), and 175 μm (zone 5). Zone 1 corresponds to the optic nerve head and was not included in the analysis.
* p: level of statistical significance in comparison between the two groups using Student’s t-test (except for sex, chi-square test). Data are mean ± standard
deviation. Bold text indicates statistically significant results (p<0.05).
** Subjects were considered myopic when spherical equivalent was < -1D. Subjects were considered hyperopic when spherical equivalent was >1D.
Abbreviations: PD, Parkinson´s disease; D, diopters; BCVA, best-corrected visual acuity; IOP, intraocular pressure.
https://doi.org/10.1371/journal.pone.0177163.t001
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patients are optic nerve atrophy and peripapillary RNFL thinning [6,9], but the secondary
impact on other deeper ocular layers, such as the choroid, have not been evaluated.
In our study, PD patients showed a 31.5% increase in the choroidal thickness in zone 2,
25.8% increase in zone 3, 21.5% increase in zone 4, and 14.2% increase in zone 5 compared
with controls. Therefore, the choroidal thickness in PD patients increased with increasing dis-
tance from the optic nerve head. The cause of this mean total increase of 24.0% in the choroi-
dal thickness of PD patients is unknown. We found that all quadrants and peripapillary sectors
provided by classic topographic OCT analysis were increased in PD compared with healthy
controls. The choroidal thickening in PD was generalized, and affected all the topographic
zones around the optical nerve.
A vascular-based influence for PD progression was recently proposed without clear results
[28–30]. Despite the observation of vascular changes in vascular parkinsonism [28], no differ-
ences are observed in white matter vascularization in idiopathic PD compared to controls [29].
In a recent study, an increased density of string vessels (vessels with collapsed basement
Table 2. Macular and peripapillary choroidal thickness and volume measured with swept-source deep range imaging optical coherence tomogra-
phy in patients with Parkinson’s disease and healthy controls.
Peripapillary choroidal thickness (μm) PD PATIENTS
Mean (SD)
CONTROLS
Mean (SD)
p
Total 153.51 (61.32) 125.01 (54.76) 0.009
Quadrants (x4)
Superior 163.01 (64.44) 146.65 (59.42) 0.121
Nasal 151.97 (52.21) 131.60 (55.05) 0.017
Inferior 127.11 (61.49) 100.23 (56.40) 0.007
Temporal 163.80 (75.96) 130.12 (53.58) 0.002*
Sectors (x6)
Superotemporal 164.11 (65.00) 142.98 (56.81) 0.101
Superonasal 168.87 (64.05) 150.28 (64.41) 0.254
Nasal 149.11 (52.76) 128.82 (56.04) 0.023
Inferotemporal 129.71 (69.92) 94.15 (50.01) 0.002*
Inferonasal 126.01 (57.13) 100.02 (58.93) 0.015
Temporal 164.04 (77.92) 130.00 (56.21) 0.002*
Peripapillary choroidal volume (mm3)
Total 3.61 (61.32) 2.94 (1.29) 0.007
Quadrants (x4)
Superior 0.96 (0.38) 0.86 (0.35) 0.098
Nasal 0.89 (0.31) 0.77 (0.32) 0.012
Inferior 0.74 (0.36) 0.59 (0.33) 0.005
Temporal 0.96 (0.44) 0.76 (0.31) 0.001*
Sectors (x6)
Superotemporal 0.64 (0.25) 0.56 (0.22) 0.081
Superonasal 0.66 (0.25) 0.59 (0.25) 0.178
Nasal 0.581 (0.21) 0.50 (0.22) 0.019
Inferotemporal 0.51 (0.27) 0.37 (0.20) 0.002*
Inferonasal 0.49 (0.22) 0.39 (0.23) 0.016
Temporal 0.64 (0.31) 0.51 (0.221) 0.001*
Bold letters indicate p<0.05. Asterisks mark significant values according to Bonferroni’s correction for multiple comparisons (p<0.005). Abbreviations: PD,
Parkinson’s disease.
https://doi.org/10.1371/journal.pone.0177163.t002
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membranes, without endothelium, and with no functional circulation) was observed in the
brain of PD patients, associated with neuronal loss [30]. Vascular ultrastructural alterations in
the choroid of PD patients have not yet been described, thus we postulate that the increased
choroidal thickness may be due to alterations in the perivascular connective tissue density
despite the previously suggested hypoperfusion in these patients [25]. Also, SS-OCT technol-
ogy provides increased depth analysis of the choroid compared to SD-OCT devices, and that
also may account for the increased choroidal thickness compared to previous studies. More
studies analyzing the macular and peripapillary choroid in PD using new SS-OCT technology
and histologic analysis are needed to corroborate our findings.
The choroid is a dynamic structure and its thickness depends on several factors. For ex-
ample, older age [31,32], higher IOP [33], higher myopia, and longer axial length [34,35] are
associated with a thinner choroid. In the present study, however, we excluded subjects with
high IOP, high myopia, and longer axial length. Several factors contribute to the conflicting
findings in PPCT with OCT; such as different measurement techniques (most of them per-
formed manually), and the dynamic and variable nature of the choroid [36]. New technologies,
such as DRI SS OCT, provide not only better delineation of the retinal layers but also a much
improved method for measuring a very large number of points in the peripapillary region and
other regions farther from the choroid. With these tools, we can determine the true shape of
the choroidal layer and possible differences due to various diseases.
Our intention was to first better understand the pattern of PPCT in normal eyes, establish
different zones based on the distribution of choroidal thickness, and to compare these areas
with eyes of patients with PD. Some histologic studies and others with SD-OCT demonstrated
that the choroid tends to be thinner around the optic nerve head compared with the subfoveal
choroid [32,35,37], which is consistent with our results. We found that the peripapillary cho-
roid follows a pattern in healthy subjects and PD patients; and is thicker superiorly and thinner
near the optic nerve head, especially inferiorly, which is consistent with other studies [38]. The
choroidal pattern is the same in PD patients, but with thicker measurements. Our findings
revealed that the peripapillary choroid was thicker in all zones in PD patients, and the differ-
ences between healthy and PD eyes tended to decrease with increasing distance from the optic
nerve head.
This study included a teaching population to determine the pattern of the topographic dis-
tribution of thickness in the peripapillary choroidal layer, and a validating population to com-
pare the thicknesses of the PD patients with an independent sample of healthy controls. Our
research team, as well as others, use this method of utilizing teaching and validating popula-
tions to avoid the overestimation effect caused by using the same subjects to create the model
and to compare that model with controls [39,40].
This study has several limitations. First, we did not collect data on axial length; however, we
demonstrated that there was no significant difference in refractive error among groups. The
axial length and refractive error variables are related, but not interchangeable, because axial
length tends to not change after the second decade of life, except in cases with some pathology.
Instead, the refractive error may fluctuate or change due to different factors [24]. The findings
from a recent study by Ikuno et al. [41] using OCT, however, suggest that refractive error and
axial length may have a similar relationship with OCT measurements. Second, the choroid can
be influenced by circadian changes [42], and we did not perform OCT examinations at the
exact same time of day in all participants; although all of the OCT studies were acquired in the
evening (between 16.00 and 20.00). Third, we only measured choroidal thickness in the right
eyes of each participant, and inter-eye differences were not assessed. Fourth, the presence of
motor symptoms in some of the patients may have affected the masking (i.e., masking was
more effective in patients with mild or non-evident symptoms). Finally, we did not establish
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the reliability of automated choroidal thickness measurements with this new SS-OCT. It
would be interesting to investigate the accuracy of this device in another study.
Imaging techniques such as OCT are noninvasive, inexpensive, and fast, and may be useful
for monitoring treatment efficacy, detecting progressive neurodegeneration, and improving
diagnostic procedures in neurologic diseases (such as making a differential diagnosis between
PD and essential tremor) [43]. In our study, we did not find that choroidal thickness was cor-
related with PD severity, but studies with a larger sample size may find significant associations.
A subgroup analysis according to PD medication was not possible as most of our patients were
prescribed combined treatment and the sample size per subgroup was not large enough to
compare the subgroups. More studies are needed to corroborate these results and to evaluate
the usefulness of choroidal measurements in PD and the role of this evaluation in clinical
practice.
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